-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA accepts Genentech vamikibart BLA for uveitic macular edema

PUBT·10/10/2026 21:50:54
Listen to the news
FDA accepts Genentech vamikibart BLA for uveitic macular edema
  • FDA accepted Genentech’s BLA for vamikibart to treat uveitic macular edema.
  • Approval decision expected by July 2027.
  • Regulatory submissions were also filed and accepted in the EU, China, Japan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on October 10, 2026, and is solely responsible for the information contained therein.